Scientists test Next-Gen mRNA flu shot
NCT ID NCT05755620
Summary
This early-stage study tested a new mRNA-based flu vaccine in 50 healthy adults aged 18-49. Researchers aimed to find a safe dose and see how well it triggers an immune response compared to a standard flu shot. Participants received one of three doses of the experimental vaccine or the licensed vaccine, with careful safety monitoring at each step.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27704, United States
Conditions
Explore the condition pages connected to this study.